1
|
Wijma R, Stangaferro ML, Masello M, Elmetwally MA, Granados GE, Amovilli F, Giordano JO. Intravaginal instillation of gonadotropin-releasing hormone analogues with an absorption enhancer induced a surge of luteinizing hormone in lactating dairy cows. J Dairy Sci 2017; 100:7626-7637. [PMID: 28711266 DOI: 10.3168/jds.2016-12513] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2016] [Accepted: 05/20/2017] [Indexed: 11/19/2022]
Abstract
Our objectives were to evaluate circulating LH concentrations after intravaginal (IVG) instillation of GnRH analogs in lactating dairy cows. In 2 experiments, lactating Holstein cows (experiment 1: n = 32; experiment 2: n = 47) received the experimental treatments 48 h after the first of 2 PGF2α treatments given 12 h apart and 7 d after a modified Ovsynch protocol (GnRH at -7 d, PGF2α at -24 h, PGF2α at -56 h, GnRH at 0 h). In experiment 1, cows were stratified by parity and randomly allocated to receive the following treatments: 2 mL of saline IVG (SAL, n = 6), 100 µg of gonadorelin (Gon) i.m. (G100-IM, n = 5), and 100 (G100, n = 7), 500 (G500, n = 8), or 1,000 µg of Gon IVG (G1000, n = 7). In experiment 2, treatments were SAL (n = 8), G100-IM (n = 8), G1000 (n = 7), 1,000 µg of Gon plus 10% citric acid (CA) IVG (G1000CA, n = 8), 80 µg of buserelin IVG (B80, n = 8), and 80 µg of buserelin plus 10% CA IVG (B80CA, n = 8). In both experiments, blood was collected every 15 min from -15 min to 4 h, and every 30 min from 4 to 6 h after treatment. Data for area under the curve (AUC), mean LH concentrations, and time to maximum LH concentration were analyzed by ANOVA with (mean LH only) or without repeated measures using PROC MIXED of SAS (version 9.4, SAS Institute Inc., Cary, NC). The proportion of cows with a surge of LH was evaluated with Fisher's exact test using PROC FREQ of SAS. In both experiments, LH concentrations were affected by treatment, time, and the treatment by time interaction. In experiment 1, the AUC for LH and maximum LH concentration were greatest for the G100-IM treatment and were greater for the G1000 than for the SAL and G500 treatments. The proportion of cows with an observed surge of LH was 100 and 0% for cows that received Gon i.m. and IVG, respectively. In experiment 2, the AUC and maximum LH concentrations were greater for the G100-IM, G1000CA, and B80CA treatments than for the other IVG treatments. The proportion of cows with a surge of LH differed by treatment (SAL = 0%, G100-IM = 100%, G1000 = 14%, G1000CA = 88%, B80 = 13%, and B80CA = 100%). For the treatments with a surge of LH, time to maximum concentration of LH was the shortest for the G100-IM treatment, intermediate for the G1000CA treatment, and the longest for cows in the B80CA treatment. In conclusion, Gon (up to 1,000 µg) absorption through intact vaginal epithelium after a single IVG instillation was insufficient to elicit a surge of LH of normal magnitude. Conversely, IVG instillation of 1,000 µg of Gon and 80 µg of buserelin with the addition of citric acid as absorption enhancer resulted in a surge of LH of similar characteristics than that induced after i.m. injection of 100 µg of Gon.
Collapse
Affiliation(s)
- R Wijma
- Department of Animal Science, Cornell University, Ithaca, NY 14853
| | - M L Stangaferro
- Department of Animal Science, Cornell University, Ithaca, NY 14853
| | - M Masello
- Department of Animal Science, Cornell University, Ithaca, NY 14853
| | - M A Elmetwally
- Department of Animal Science, Cornell University, Ithaca, NY 14853
| | - G E Granados
- Department of Animal Science, Cornell University, Ithaca, NY 14853
| | - F Amovilli
- Department of Animal Science, Cornell University, Ithaca, NY 14853
| | - J O Giordano
- Department of Animal Science, Cornell University, Ithaca, NY 14853.
| |
Collapse
|
2
|
Early-loaded laser-sintered versus acid-etched one-piece dental implants for mandibular premolars replacement: a preliminary study. IMPLANT DENT 2014; 23:565-9. [PMID: 25192156 DOI: 10.1097/id.0000000000000133] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
AIM Early loading of dental implants can simplify treatment and increase patient's satisfaction. This 1-year preliminary clinical trial aimed to clinically and radiographically evaluate early-loaded one-piece implants that had either laser-sintered or acid-etched surfaces. MATERIALS AND METHODS Sixty patients with missing mandibular premolars received 60 implants of one-piece type that were subjected to early loading after 3 weeks of initial placement. Group 1 included 30 implants with laser-sintered surface while group 2 included 30 implants with acid-etched surface. Patients were recalled for follow-up at 1, 3, 6, and 12 months after loading. RESULTS No significant difference (P > 0.05) was found between the 2 implant groups at 1, 3, 6, and 12 months of implant loading, and all implants were considered successful after 12 months of follow-up. CONCLUSIONS These preliminary results suggest that these implants are associated with satisfactory clinical and radiographic outcomes. Laser versus acid-etched surface treatments did not show any significant difference among different clinical measures or radiographic evaluations at different follow-up times. However, wider application for longer follow-up periods is required for further conclusive recommendations.
Collapse
|
3
|
El-Gammal M, Ghoneem N, Tawfik H, Madina MA, Maria OM. LASER sintered one-piece early-loaded dental implants for mandibular premolars replacement. J ORAL IMPLANTOL 2013; 41:56-62. [PMID: 23413822 DOI: 10.1563/aaid-joi-d-12-00210] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
This study was designed to evaluate laser-sintered early-loaded 1-piece implants (OPI) based on clinical and radiographic findings. Thirty OPI were placed in the mandibular premolar area and subjected to early loading after 3 weeks of initial placement; patients were followed up for 6 months. Clinical evaluation included pocket depth, gingival health, implant stability, and esthetics. Periapical radiographs were used to measure the marginal bone loss (MBL). All implants were considered successful resulting in a survival rate of 100%. A remarkable difference (P < 0.01) existed when comparing MBL levels at 1 month with those at 3 and 6 months. Significant differences (P < 0.01) existed when comparing implant stability at 1 month to 3 months and at 3 months to 6 months. Moreover, significant differences (P < 0.01) were observed when comparing peri-implant probing depth at 1 month to that at 3 and 6 months on both the mesial and distal sides. The mean value of pink esthetic score was 11 at time of final restoration. The laser-treated early-loaded OPI design is associated with satisfactory clinical and radiographic follow-up results and it is a good alternative to the 2-piece design.
Collapse
Affiliation(s)
- Mona El-Gammal
- 1 Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Mansoura University, Mansoura, Egypt
| | | | | | | | | |
Collapse
|
4
|
Koushik K, Sunkara G, Gwilt P, Kompella UB. Pathways and kinetics of deslorelin degradation in an airway epithelial cell line (Calu-1). Pharm Res 2003; 20:779-87. [PMID: 12751634 DOI: 10.1023/a:1023489620394] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
PURPOSE The objective of this study is to investigate the pathways and kinetics of degradation of deslorelin, pGlu1-His2-Trp3-Ser4-Tyr5-D-Trp6-Leu7-Arg8-ProNHEt9 (Des1-9), in a human airway epithelial cell line (Calu-1). METHODS The degradation of deslorelin in membrane and cytosolic fractions of Calu-1 cells was studied at 37 degrees C up to 24 h. The degradation products were separated using HPLC and identified by amino acid analysis, sequencing, and mass spectrometry. The rate constants for deslorelin degradation and the formation of degradation products were determined by fitting the concentration vs. time data to pharmacokinetic models using WinNonlin. The effect of enzyme inhibitors, captopril, phosphoramidon, and disodium EDTA on deslorelin degradation was also assessed. RESULTS Des1-3, Des4-9, and Des5-9 were the deslorelin fragments detected in the membrane fraction. Apart from these degradation products. Des5-7 was also detected in the cytosolic fraction. The deslorelin degradation was 8.5 times faster in the cytosolic fraction compared to the membrane fraction. The disappearance of deslorelin and the kinetics of degradation products could be explained by simple 2 compartment iv bolus model and 1 compartment absorption model, respectively. EDTA and captopril decreased deslorelin degradation in the membrane and cytosolic fractions. CONCLUSIONS Deslorelin is initially cleaved at the 3-4 bond in the membrane and cytosolic fractions, possibly by a metalloendopeptidase and/or angiotensin converting enzyme, with the degradation being more rapid in the cytosol.
Collapse
Affiliation(s)
- Kavitha Koushik
- Department of Pharmaceutical Sciences, 986025 University of Nebraska Medical Center, Omaha, Nebraska 68198, USA
| | | | | | | |
Collapse
|
5
|
Wen JY, Ledger R, McLeod BJ, Davies NM, Butt AG, Tucker IG. Enzymatic degradation of luteinizing hormone releasing hormone (LHRH) by mucosal homogenates from the intestine of the common brushtail possum (Trichosurus vulpecula). Life Sci 2002; 71:3019-30. [PMID: 12384185 DOI: 10.1016/s0024-3205(02)02163-x] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The peptidolytic activity of fresh and frozen mucosal homogenates from five regions (duodenum, jejunum, ileum, caecum and colon) of possum intestine from Trichosurus vulpecula towards human Luteinizing Hormone Releasing Hormone (LHRH) was investigated. The rank of order of specific peptidolytic activity of the mucosal homogenates was jejunum > ileum > caecum> duodenum = colon, with a 3 to 4 fold difference between the least and the most active segment in both frozen and fresh samples. The formation of peptides LHRH (1-3), LHRH (1-4) and LHRH (1-5) suggest endopepetidase-24.18, endopeptidase-24.15 and angiotensin converting enzyme (ACE) might be responsible for the peptide degradation in mucosal homogenates. The inhibition of LHRH degradation by mucosal homogenates was evaluated in four regions (jejunum, ileum, caecum and colon) of possum intestine. Ethylenediaminetetraacetic acid (EDTA, 5 mM), sodium deoxycholate (SDA, 10 mM) and bacitracin (3.5 or 9 mM) inhibited the degradation of LHRH in mucosal homogenates from small intestine and hindgut. However, the serine protease inhibitor, soybean trypsin-chymotrypsin inhibitor (SBTI), did not prevent degradation of LHRH. It is concluded that combining peptides with inhibitors may enhance oral delivery of bioactive peptides or proteins to possums.
Collapse
Affiliation(s)
- J Y Wen
- School of Pharmacy, University of Otago, PO Box 913, Dunedin, New Zealand
| | | | | | | | | | | |
Collapse
|
6
|
Wen J, Davies N, Ledger R, Butt G, McLeod B, Tucker IG. Isocratic liquid chromatographic assay for monitoring the degradation of luteinizing hormone releasing hormone by extracts from the gastrointestinal tract of possums. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 779:221-7. [PMID: 12361736 DOI: 10.1016/s1570-0232(02)00373-2] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
A simple HPLC method to separate human luteinizing hormone releasing hormone (LHRH) from its metabolites using an isocratic elution is described. Intact LHRH and five metabolites were separated in 11.4 min. The calibration curve (peak area versus concentration) was linear over the concentration range 1.25-35 microg/ml (r(2)=0.99) with the intercept not significantly different from zero (P>0.05). Intra-day and inter-day variability of the assay was less than 5% for repeat injections of 5, 14.5 and 29 microg/ml. The method was applied to evaluate the susceptibility of LHRH to enzymes present in the lumen and mucosal extracts of the gastrointestinal tract of possums. The major degradation products of LHRH were identified by HPLC separation, amino acid analysis and mass spectrometry as LHRH (1-5), LHRH (1-4), LHRH (1-3) and LHRH (3-4).
Collapse
Affiliation(s)
- Jingyuan Wen
- School of Pharmacy, University of Otago, P.O. Box 913, Dunedin, New Zealand
| | | | | | | | | | | |
Collapse
|
7
|
Wen JY, Ledger R, Butt AG, McLeod BJ, Davies NM, Tucker IG. Inhibition of proteolysis in luminal extracts from the intestine of the brushtail possum. J Pharm Pharmacol 2002; 54:1365-72. [PMID: 12396298 DOI: 10.1211/002235702760345446] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
Abstract
The proteolytic activity of luminal extracts from five regions (duodenum, jejunum, ileum, caecum and colon) of the brushtail possum intestine towards bovine serum albumin (BSA) and human luteinizing hormone releasing hormone (LHRH) was investigated. There were no significant differences in degradation rates between fresh and previously frozen extracts from any region of the possum intestine. The inhibition of degradation of BSA by luminal extracts from two regions (jejunum and ileum) and of LHRH from four regions (jejunum, ileum, caecum and colon) was evaluated. Soybean trypsin-chymotrypsin inhibitor (SBTI), sodium deoxycholate, Carbopol 934P, bacitracin and bestatin significantly inhibited the degradation of both LHRH and BSA (P < 0.05). SBTI almost totally inhibited the proteolysis of BSA and the peptidolysis of LHRH in extracts from the small intestine. This finding suggests that serine proteases such as chymotrypsin are responsible for the protein and peptide degradation in luminal extracts. It is concluded that including serine protease inhibitors in a formulation may enhance oral delivery of bioactive peptides and proteins to possums.
Collapse
Affiliation(s)
- J-Y Wen
- School of Pharmacy, University of Otago, PO Box 913, Dunedin, New Zealand
| | | | | | | | | | | |
Collapse
|
8
|
Ledger R, Tucker IG, Walker GF. Quantitative capillary electrophoresis assay for the proteolytic stability of luteinizing hormone-releasing hormones. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 769:235-42. [PMID: 11996489 DOI: 10.1016/s1570-0232(01)00564-5] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
A rapid and simple capillary electrophoresis (CE) assay for measuring the stability of luteinizing hormone-releasing hormone (LHRH) analogues in the presence of intestinal enzymes has been developed and validated. Buffer pH and sample stacking were important factors in controlling resolution and reproducibility. The CE assay for human (h) and salmon LHRH analogues between 0.05 and 0.25 mM was linear for peak height versus concentration (r2>0.99). Analysis of hLHRH at 0.1 mM had an intra-day relative standard deviation of 1.25% and an inter-day relative standard deviation of 5.0%. The method was applied to the stability of LHRH analogues in salmon intestinal digests.
Collapse
Affiliation(s)
- Robin Ledger
- School of Pharmacy, University of Otago, Dunedin, New Zealand.
| | | | | |
Collapse
|
9
|
Acartürk F, Parlatan ZI, Saracoğlu OF. Comparison of vaginal aminopeptidase enzymatic activities in various animals and in humans. J Pharm Pharmacol 2001; 53:1499-504. [PMID: 11732752 DOI: 10.1211/0022357011778034] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
Abstract
The specific enzymatic activity of four different aminopeptidases (aminopeptidase N, leucine aminopeptidase, aminopeptidase A and aminopeptidase B) in vaginal homogenates from rabbit, rat, guinea-pig, sheep and humans was compared. The purpose of the study was to find an appropriate animal model that can be used in degradation studies of protein and peptide drugs. Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B. The vaginal aminopeptidase enzymatic activity of different species was determined spectrofluorometrically. The inhibition of aminopeptidase activity in the presence of bestatin and puromycin inhibitors was also investigated. The results showed the presence of aminopeptidase enzymatic activity in all vaginal homogenates in the order: sheep > guinea-pig > rabbit > or = human > or = rat. Based on the results of the hydrolysis and inhibition of the 4-methoxy-2-naphthylamide substrates, it was difficult to have an exact decision on the aminopeptidase type in the vaginal homogenates from the species studied. It was found that the aminopeptidase activity in rat, rabbit and humans was not statistically different. Therefore, we suggest that rats and rabbits could be used as model animals for vaginal enzymatic activity studies and for determination of the degradation of protein and peptide drugs in the vagina.
Collapse
Affiliation(s)
- F Acartürk
- Department of Pharmaceutical Technology, Faculty of Pharmacy, Gazi University, Etiler, Ankara, Turkey.
| | | | | |
Collapse
|
10
|
Yang X, Ma JK, Malanga CJ, Rojanasakul Y. Characterization of proteolytic activities of pulmonary alveolar epithelium. Int J Pharm 2000; 195:93-101. [PMID: 10675687 DOI: 10.1016/s0378-5173(99)00377-4] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Pulmonary alveolar type I epithelial cell and its progenitor, type II cell, present major transport and enzyme barriers for systemic delivery of pulmonary administered peptide drugs. The present study investigates the effect of cellular differentiation of type II to type I cells on their proteolytic activities, and evaluates the suitability of a continuous lung cell line, A549, for drug transport and degradation studies. High performance liquid chromatography was used to assess the degradation kinetics of two model peptide substrates, luteinizing hormone releasing hormone (LHRH) and [D-Ala(6)10-fold decrease in proteolytic activities for LHRH, as compared to type II cells. The continuous lung cell line A549 formed leaky monolayers and exhibited similar enzyme activities to the primary type II cells. The responsible enzymes for degradation of LHRH in type II and A549 cells were angiotensin converting enzyme (ACE), EP24.11, and EP24.15. In contrast, no EP24.15 or ACE activity was observed in type I-like pneumocytes and only a weak EP24.11 activity was detected. In all cell types, the degradation rate of [D-Ala(6)]-LHRH was about 3-8 times lower than that of LHRH. This peptide analog was resistant to degradation by EP24.15 and EP24.11, but was susceptible to ACE-mediated cleavage.
Collapse
Affiliation(s)
- X Yang
- West Virginia University, School of Pharmacy, Department of Basic Pharmaceutical Sciences, Health Sciences Center, Morgantown, WV 26506, USA
| | | | | | | |
Collapse
|
11
|
Yang X, Rojanasakul Y, Wang L, Ma JY, Ma JK. Enzymatic degradation of luteinizing hormone releasing hormone (LHRH)/[D-Ala6]-LHRH in lung pneumocytes. Pharm Res 1998; 15:1480-4. [PMID: 9755904 DOI: 10.1023/a:1011926310666] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
PURPOSE To investigate the cellular proteolytic activities of various lung pneumocytes using luteinizing hormone releasing hormone (LHRH) and [D-Ala6]-LHRH as model peptide substrates. METHODS HPLC analysis was used to investigate the degradation kinetics of LHRH/[D-Ala6]-LHRH and to identify their degradation products in isolated lung pneumocytes. RESULTS Pulmonary macrophages exhibited the strongest proteolytic activity against LHRH)/[D-Ala6]-LHRH, followed by type II and type I-like pneumocytes. Three major degradation products of LHRH, namely LHRH 4-10, LHRH 6-10, and LHRH 7-10, were identified in macrophages and type II pneumocytes, whereas in type I-like pneumocytes only the LHRH 7-10 was found. Co-incubation of the cells with known enzyme inhibitors including captopril (an ACE inhibitor), thiorphan (an EP24.11 inhibitor), and EDTA (an EP24.15 inhibitor) inhibited the formation of LHRH 4-10, LHRH 7-10, and LHRH 6-10 respectively. In all cell types, the degradation rate of [D-Ala6]-LHRH was about 3-8 times lower than that of LHRH. This peptide analog was resistant to degradation by EP24.15 and EP24.11, but was susceptible to ACE. CONCLUSIONS ACE, EP24.11, and EP24.15 are the major enzymes responsible for the degradation of LHRH in macrophages and type II pneumocytes. The magnitude of peptidase activities in these cell types are: EP24.15 > EP24.11 approximately ACE. No EP24.15 or ACE activity was observed in type I-like pneumocytes and only a weak EP24.11 activity was detected.
Collapse
Affiliation(s)
- X Yang
- Department of Basic Pharmaceutical Sciences, West Virginia University, School of Pharmacy, Health Sciences Center, Morgantown 26506, USA
| | | | | | | | | |
Collapse
|